Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM04690 in moderate to severe knee osteoarthritis
NCT02095548Phase 1Completed
- Sponsor
- Biosplice Therapeutics
- Start
- Mar 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lorecivivint in osteoarthritis (OA) (4 arms), sponsored by Biosplice Therapeutics. Primary endpoints: Adverse Events and Dose Limiting Toxicity at 24 weeks, Bone Loss measured by CT at 24 weeks and 1 more. Started Mar 2014; status: completed.
02
Drugs
lorecivivint
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02095548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095548.